Tenax presents Phase 3 LEVEL data showing TNX-103 boosts 6-minute walk distance in lower baseline subgroup

Reuters2026/08/29 12:21

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Tenax Therapeutics presented additional Phase 3 LEVEL results for TNX-103 in a late-breaking session at ESC Congress 2026.
The trial missed its main efficacy goals in the overall study population, raising uncertainty around the current registrational strategy.
Subgroup results pointed to clearer functional benefit in more impaired patients, supported by improvements in biomarkers and cardiac pressure measures.
Management plans to redesign LEVEL-2 to enrich enrollment toward patients most likely to respond, aiming to preserve a path to approval.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tenax Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608290821PRIMZONEFULLFEED9818036) on August 29, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Tenax presents Phase 3 LEVEL data showing TNX-103 boosts 6-minute walk distance in lower baseline subgroup

You may also like

Crypto prices